tetano
Editor, Senior Moderator
Nat Commun
. 2022 Oct 3;13(1):5801.
doi: 10.1038/s41467-022-33042-0.
Immunogenicity decay and case incidence six months post Sinovac-CoronaVac vaccine in autoimmune rheumatic diseases patients
Clovis A Silva[SUP] 1 [/SUP], Ana C Medeiros-Ribeiro[SUP] 2 [/SUP], Leonard V K Kupa[SUP] 2 [/SUP], Emily F N Yuki[SUP] 2 [/SUP], Sandra G Pasoto[SUP] 2 [/SUP], Carla G S Saad[SUP] 2 [/SUP], Solange R G Fusco[SUP] 2 [/SUP], Rosa M R Pereira[SUP] 2 [/SUP], Samuel K Shinjo[SUP] 2 [/SUP], Ari S R Halpern[SUP] 2 [/SUP], Eduardo F Borba[SUP] 2 [/SUP], Fernando H C Souza[SUP] 2 [/SUP], Lissiane K N Guedes[SUP] 2 [/SUP], Renata Miossi[SUP] 2 [/SUP], Karina R Bonfiglioli[SUP] 2 [/SUP], Diogo S Domiciano[SUP] 2 [/SUP], Andrea Y Shimabuco[SUP] 2 [/SUP], Danieli C O Andrade[SUP] 2 [/SUP], Luciana P C Seguro[SUP] 2 [/SUP], Ricardo Fuller[SUP] 2 [/SUP], Percival D Sampaio-Barros[SUP] 2 [/SUP], Ana P L Assad[SUP] 2 [/SUP], Julio C B Moraes[SUP] 2 [/SUP], Claudia Goldenstein-Schainberg[SUP] 2 [/SUP], Henrique A M Giardini[SUP] 2 [/SUP], Henrique C Silva[SUP] 2 [/SUP], Victor A O Martins[SUP] 2 [/SUP], Lorena E B Villamarin[SUP] 2 [/SUP], Renata S Novellino[SUP] 2 [/SUP], Lucas P Sales[SUP] 2 [/SUP], Carlo S R Araújo[SUP] 2 [/SUP], Matheus S R Silva[SUP] 2 [/SUP], Dilson M N Filho[SUP] 2 [/SUP], Marta H Lopes[SUP] 3 [/SUP], Alberto J S Duarte[SUP] 4 [/SUP], Esper G Kallas[SUP] 3 [/SUP], Nadia E Aikawa[SUP] 1 [/SUP], Eloisa Bonfa[SUP] 5 [/SUP]
Affiliations
Abstract
The determination of durability and vaccine-associated protection is essential for booster doses strategies, however data on the stability of SARS-CoV-2 immunity are scarce. Here we assess anti-SARS-CoV-2 immunogenicity decay and incident cases six months after the 2[SUP]nd[/SUP] dose of Sinovac-CoronaVac inactivated vaccine (D210) in 828 autoimmune rheumatic diseases patients compared with 207 age/sex-balanced control individuals. The primary outcome is the presence of anti-S1/S2 SARS-CoV-2 IgG at 6 months compared to 6 weeks after 2nd vaccine dose for decay evaluation. Secondary outcomes are presence of neutralizing antibodies, percent inhibition by neutralizing, geometric mean titers and cumulative incident cases at 6 months after 2nd dose. Anti-S1/S2 IgG positivity and titers reduce to 23.8% and 38% in patients (p < 0.001) during the six-month follow up and 20% and 51% in controls (p < 0.001), respectively. Neutralizing antibodies positivity and percent inhibition declines 41% and 54% in patients (p < 0.001) and 39.7% and 47% in controls (p < 0.001). Multivariate logistic regression analysis show males (OR = 0.56;95% CI0.40-0.79), prednisone (OR = 0.56; 95% CI0.41-0.76), anti-TNF (OR = 0.66;95% CI0.45-0.96), abatacept (OR = 0.29; 95% CI0.15-0.56) and rituximab (OR = 0.32;95% CI0.11-0.90) associate with a substantial reduction in IgG response at day 210 in patients. Although cellular immunity was not assessed, a decrease of COVID-19 cases (from 27.5 to 8.1/100 person-years; p < 0.001) is observed despite the concomitant emergence and spread of the Delta variant. Altogether we show a reduction in immunity 6-months of Sinovac-CoronaVac 2nd dose, particularly in males and those under immunosuppressives therapies, without a concomitant rise in COVID-19 cases. (CoronavRheum clinicaltrials.gov:NCT04754698).
. 2022 Oct 3;13(1):5801.
doi: 10.1038/s41467-022-33042-0.
Immunogenicity decay and case incidence six months post Sinovac-CoronaVac vaccine in autoimmune rheumatic diseases patients
Clovis A Silva[SUP] 1 [/SUP], Ana C Medeiros-Ribeiro[SUP] 2 [/SUP], Leonard V K Kupa[SUP] 2 [/SUP], Emily F N Yuki[SUP] 2 [/SUP], Sandra G Pasoto[SUP] 2 [/SUP], Carla G S Saad[SUP] 2 [/SUP], Solange R G Fusco[SUP] 2 [/SUP], Rosa M R Pereira[SUP] 2 [/SUP], Samuel K Shinjo[SUP] 2 [/SUP], Ari S R Halpern[SUP] 2 [/SUP], Eduardo F Borba[SUP] 2 [/SUP], Fernando H C Souza[SUP] 2 [/SUP], Lissiane K N Guedes[SUP] 2 [/SUP], Renata Miossi[SUP] 2 [/SUP], Karina R Bonfiglioli[SUP] 2 [/SUP], Diogo S Domiciano[SUP] 2 [/SUP], Andrea Y Shimabuco[SUP] 2 [/SUP], Danieli C O Andrade[SUP] 2 [/SUP], Luciana P C Seguro[SUP] 2 [/SUP], Ricardo Fuller[SUP] 2 [/SUP], Percival D Sampaio-Barros[SUP] 2 [/SUP], Ana P L Assad[SUP] 2 [/SUP], Julio C B Moraes[SUP] 2 [/SUP], Claudia Goldenstein-Schainberg[SUP] 2 [/SUP], Henrique A M Giardini[SUP] 2 [/SUP], Henrique C Silva[SUP] 2 [/SUP], Victor A O Martins[SUP] 2 [/SUP], Lorena E B Villamarin[SUP] 2 [/SUP], Renata S Novellino[SUP] 2 [/SUP], Lucas P Sales[SUP] 2 [/SUP], Carlo S R Araújo[SUP] 2 [/SUP], Matheus S R Silva[SUP] 2 [/SUP], Dilson M N Filho[SUP] 2 [/SUP], Marta H Lopes[SUP] 3 [/SUP], Alberto J S Duarte[SUP] 4 [/SUP], Esper G Kallas[SUP] 3 [/SUP], Nadia E Aikawa[SUP] 1 [/SUP], Eloisa Bonfa[SUP] 5 [/SUP]
Affiliations
- PMID: 36192386
- DOI: 10.1038/s41467-022-33042-0
Abstract
The determination of durability and vaccine-associated protection is essential for booster doses strategies, however data on the stability of SARS-CoV-2 immunity are scarce. Here we assess anti-SARS-CoV-2 immunogenicity decay and incident cases six months after the 2[SUP]nd[/SUP] dose of Sinovac-CoronaVac inactivated vaccine (D210) in 828 autoimmune rheumatic diseases patients compared with 207 age/sex-balanced control individuals. The primary outcome is the presence of anti-S1/S2 SARS-CoV-2 IgG at 6 months compared to 6 weeks after 2nd vaccine dose for decay evaluation. Secondary outcomes are presence of neutralizing antibodies, percent inhibition by neutralizing, geometric mean titers and cumulative incident cases at 6 months after 2nd dose. Anti-S1/S2 IgG positivity and titers reduce to 23.8% and 38% in patients (p < 0.001) during the six-month follow up and 20% and 51% in controls (p < 0.001), respectively. Neutralizing antibodies positivity and percent inhibition declines 41% and 54% in patients (p < 0.001) and 39.7% and 47% in controls (p < 0.001). Multivariate logistic regression analysis show males (OR = 0.56;95% CI0.40-0.79), prednisone (OR = 0.56; 95% CI0.41-0.76), anti-TNF (OR = 0.66;95% CI0.45-0.96), abatacept (OR = 0.29; 95% CI0.15-0.56) and rituximab (OR = 0.32;95% CI0.11-0.90) associate with a substantial reduction in IgG response at day 210 in patients. Although cellular immunity was not assessed, a decrease of COVID-19 cases (from 27.5 to 8.1/100 person-years; p < 0.001) is observed despite the concomitant emergence and spread of the Delta variant. Altogether we show a reduction in immunity 6-months of Sinovac-CoronaVac 2nd dose, particularly in males and those under immunosuppressives therapies, without a concomitant rise in COVID-19 cases. (CoronavRheum clinicaltrials.gov:NCT04754698).